Table 1.
Study ID | Study Design and Follow-up Period | Characteristic of the Participants | Intervention Arm/Control Arm | Outcome(s) | Allocation Bias | Performance Bias | Detection Bias | Attrition Bias | Reporting Bias | Other Biases |
---|---|---|---|---|---|---|---|---|---|---|
Johnston 2004 | Randomized crossover trial; 1-week washout period Follow-up: 60 minutes | T2DM; n = 10; not on OADs From United States |
|
|
? | ↓ | ↓ | ↓ | ↑ | ↓ |
Johnston 2008 | RCT Follow-up: 12 weeks | T2DM; n = 27; on OADs; age range = 20-80 years; mean age = 63.0 (±4.1) From United States |
|
|
↓ | ↑ | ↓ | ↓ | ↓ | ↓ |
Johnston 2009 | RCT Follow-up: 12 weeks | T2DM; n = 27; on OADs; age range = 20-80 years; mean age = 63.0 (±4.1) From United States |
|
|
↓ | ↑ | ↓ | ↓ | ↓ | ↓ |
Johnston 2010 | Randomized crossover trial; 1-week washout period Follow-up: 2 hours | T2DM; n = 9; on OADs; mean age = 69 (±2) years From United States |
|
|
? | ? | ↓ | ↓ | ↓ | ↓ |
Liatis 2010 | Before-after (2 groups—low and high GI mixed meal); 1 week (±2 days) washout period Follow-up: 2 hours | T2DM; n = 16; on OADs or diet alone Low GI group: Mean age = 57.4 (±8.0) years; mean duration of DM = 3.6 (±4.0) years High GI group: Mean age = 61.4 (±8.4) years; mean duration of DM = 4.8 (±3.5) years From Greece |
|
|
↓ | ↓ | ↓ | ↓ | ↓ | ↓ |
Mahmoodi 2013 | Nonrandomized controlled trial Follow-up: 1 month | T2DM; n = 60; on OADs; age range = 30-60 years From Iran |
|
|
↑ | ↑ | ↓ | ↓ | ↑ | ↑ |
Mitrou 2010 | RCT Follow-up: 4 hours | T1DM; n = 10; on insulin; mean age = 32 (±3) years; mean HbA1c = 6.7% (±0.2%); mean duration of DM = 14 (±3) years From Greece |
|
|
? | ? | ↓ | ↓ | ↓ | ↓ |
Van Dijk 2012 | Randomized crossover trial; 1-week washout period Follow-up: 1 week | T2DM; n = 12; on OADs; mean age = 65 (±1) years; mean HbA1c = 6.6% (±0.2%) From Netherlands |
|
|
? | ? | ↓ | ↓ | ? | ↓ |
White 2007 | Randomized crossover trial; 3-5 days washout period Follow-up: 2 days | T2DM; n = 11; on OADs; age range = 40-72 years; FPG = 7.6 (±0.3) mmol/L; mean HbA1c = 6.2% (±0.2%); mean duration of DM = 4.9 (±1.0) years From United States |
|
|
↑ | ? | ↓ | ↓ | ↑ | ↓ |
Yoon 2012 | RCT Follow-up: 8 weeks | T2DM; n = 72; not on OADs; mean age = 52.8 (±9.9); FPG of 7.0-15.0 mmol/L and HbA1c of 7.0% to 12.0% From South Korea |
|
|
↓ | ↓ | ↓ | ↓ | ↓ | ↓ |
Ebrahimi 2009 | RCT Follow-up: 8 weeks | T2DM; n = 65; mean age = 55.8 (±11.4) From Iran |
|
|
? | ↑ | ↓ | ↓ | ? | ↓ |
Nosrati 2013 | Randomized crossover trial; 1-week washout period Follow-up: 90 minutes | T2DM; n = 32; on OADs; mean age = 47.25 (±16.82) From Iran |
|
|
↓ | ? | ↓ | ↓ | ↓ | ↓ |
Abbreviations: T2DM, type 2 diabetes mellitus; OAD, orally administered drug; RCT, randomized controlled drug; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AE, adverse event; AUC, area under the curve; GI, glycemic index; FPG, fasting blood/plasma glucose; BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.